Copanlisib

Phase 2

Clovis Oncology, Inc. (CLVS)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jan '27

CLVSPhase 2

Copanlisib Phase 2 Est. Readout

Copanlisib• Metastatic Castration-resistant Prostate Cancer13

Jan 2027~Confirmed

CT.gov

00%

Competitive Landscape

2 competitors in Metastatic Castration-resistant Prostate Cancer

LLY[Lu-177]-PNT2002

Phase 3

XNCRvudalimab monotherapy

Phase 2

View Full Landscape

Drug Information

Target Indication

Metastatic Castration-resistant Prostate Cancer

Clinical Trial

NCT04253262

Last updated: 8/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

CLVS

Clovis Oncology, Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

rucaparibPhase 3

Metastatic Breast Cancer

CO-1.01Phase 2

Metastatic Pancreatic Adenocarcinoma

CisplatinPhase 2

Breast Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts